Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s

Teva has added yet another critical failure for laquinimod, which may finally be put on the chopping block.

The company’s partners at Active Biotech $ACTI announced that their Phase II study for Huntington’s disease failed, which comes on top of multiple failures in multiple sclerosis.